Drug · DIN 02468751
TRUMENBA
BIVALENT RECOMBINANT LIPOPROTEIN (RLP2086). PREFILLED SYRINGE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since January 31, 2018; first marketed January 31, 2018.
- Drug Identification Number (DIN)
- 02468751
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Schedule d
- Dosage form
- Suspension
- Route
- Intramuscular
- Therapeutic class (ATC)
- Meningococcal vaccines J07AH
- Class
- Human
- Record last updated
- September 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| NEISSERIA MENINGITIDIS GRP B RECOMBINANT LIPOPROTEIN 2086 SUBFAMILY A | 60 MCG | 0.5 ML |
| NEISSERIA MENINGITIDIS GRP B RECOMBINANT LIPOPROTEIN 2086 SUBFAMILY B | 60 MCG | 0.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 5, 2017: NOC 19881New Drug Submission (NDS)